These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28755184)

  • 1. Tyrosinemia and Liver Transplantation: Experience at CHU Sainte-Justine.
    Alvarez F; Mitchell GA
    Adv Exp Med Biol; 2017; 959():67-73. PubMed ID: 28755184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec.
    Halac U; Dubois J; Mitchell GA
    Adv Exp Med Biol; 2017; 959():75-83. PubMed ID: 28755185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hereditary Tyrosinemia Type 1 in Turkey.
    Aktuglu-Zeybek AC; Kiykim E; Cansever MS
    Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
    Raimann E; Cornejo V; Arias C; Cabello JF; Castro G; Fernández E; de la Parra A
    Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver Transplantation for Hereditary Tyrosinaemia Type 1 in the United Kingdom.
    McKiernan P
    Adv Exp Med Biol; 2017; 959():85-91. PubMed ID: 28755186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genetic tyrosinemias.
    Scott CR
    Am J Med Genet C Semin Med Genet; 2006 May; 142C(2):121-6. PubMed ID: 16602095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
    Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
    Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
    Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.
    Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM
    Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1.
    Tanguay RM; Angileri F; Vogel A
    Adv Exp Med Biol; 2017; 959():49-64. PubMed ID: 28755183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Québec NTBC Study.
    ; Alvarez F; Atkinson S; Bouchard M; Brunel-Guitton C; Buhas D; Bussières JF; Dubois J; Fenyves D; Goodyer P; Gosselin M; Halac U; Labbé P; Laframboise R; Maranda B; Melançon S; Merouani A; Mitchell GA; Mitchell J; Parizeault G; Pelletier L; Phan V; Turcotte JF
    Adv Exp Med Biol; 2017; 959():187-195. PubMed ID: 28755196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
    Luijerink MC; Jacobs SM; van Beurden EA; Koornneef LP; Klomp LW; Berger R; van den Berg IE
    J Hepatol; 2003 Dec; 39(6):901-9. PubMed ID: 14642604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosinemia Type I in Japan: A Report of Five Cases.
    Nakamura K; Ito M; Shigematsu Y; Endo F
    Adv Exp Med Biol; 2017; 959():133-138. PubMed ID: 28755191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
    Morrow G; Tanguay RM
    Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitisinone in the treatment of hereditary tyrosinaemia type 1.
    McKiernan PJ
    Drugs; 2006; 66(6):743-50. PubMed ID: 16706549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients.
    van Ginkel WG; Jahja R; Huijbregts SCJ; van Spronsen FJ
    Adv Exp Med Biol; 2017; 959():111-122. PubMed ID: 28755189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice.
    Hillgartner MA; Coker SB; Koenig AE; Moore ME; Barnby E; MacGregor GG
    J Inherit Metab Dis; 2016 Sep; 39(5):673-682. PubMed ID: 27271696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTBC and Correction of Renal Dysfunction.
    Maiorana A; Dionisi-Vici C
    Adv Exp Med Biol; 2017; 959():93-100. PubMed ID: 28755187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
    van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
    Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live donor liver transplantation for type 1 tyrosinemia: An analysis of 15 patients.
    Karaca CA; Yilmaz C; Farajov R; Iakobadze Z; Aydogdu S; Kilic M
    Pediatr Transplant; 2019 Sep; 23(6):e13498. PubMed ID: 31155831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.